6,094
Views
37
CrossRef citations to date
0
Altmetric
Report

July 2017 ENCALS statement on edaravone

ORCID Icon, , , , , , , , , , , , , , , , , , , , ORCID Icon, , , , , , , , ORCID Icon, , , , , , , , , , , ORCID Icon & ORCID Icon show all
Pages 471-474 | Received 11 Aug 2017, Accepted 15 Aug 2017, Published online: 04 Oct 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

John Turnbull. (2018) Is edaravone harmful? (A placebo is not a control). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:7-8, pages 477-482.
Read now
Letizia Mazzini, Daniela Ferrari, Pavle R Andjus, Leonora Buzanska, Roberto Cantello, Fabiola De Marchi, Maurizio Gelati, Rashid Giniatullin, Joel C. Glover, Mariagrazia Grilli, Elena N. Kozlova, Margherita Maioli, Dinko Mitrečić, Augustas Pivoriunas, Rosario Sanchez-Pernaute, Anna Sarnowska & Angelo L. Vescovi. (2018) Advances in stem cell therapy for amyotrophic lateral sclerosis. Expert Opinion on Biological Therapy 18:8, pages 865-881.
Read now
Crystal Jing Jing Yeo & Zachary Simmons. (2018) Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:3-4, pages 167-172.
Read now

Articles from other publishers (34)

Nadia Rabeh, Baraa Hajjar, Jude O. Maraka, Ashwin F. Sammanasunathan, Mohammed Khan, Saif M.I. Alkhaaldi, Samy Mansour, Rashed T. Almheiri, Hamdan Hamdan & Khaled S. Abd-Elrahman. (2023) Targeting mGluR group III for the treatment of neurodegenerative diseases. Biomedicine & Pharmacotherapy 168, pages 115733.
Crossref
Hristelina Ilieva, Mithila Vullaganti & Justin Kwan. (2023) Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis. BMJ, pages e075037.
Crossref
Fabiola De Marchi, Toni Franjkic, Paride Schito, Tommaso Russo, Jerneja Nimac, Anna A. Chami, Angelica Mele, Lea Vidatic, Jasna Kriz, Jean-Pierre Julien, Gordana Apic, Robert B. Russell, Boris Rogelj, Jason R. Cannon, Marco Baralle, Federica Agosta, Silva Hecimovic, Letizia Mazzini, Emanuele Buratti & Ivana Munitic. (2023) Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder. Biomedicines 11:6, pages 1599.
Crossref
Stephen A. Johnson, Ton Fang, Fabiola De Marchi, Dylan Neel, Donatienne Van Weehaeghe, James D. Berry & Sabrina Paganoni. (2022) Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents. Drugs 82:13, pages 1367-1388.
Crossref
Thi-Thuyet Truong, Wen-Tai Chiu, Yi-Shyun Lai, Hsien Huang, Xiaoning Jiang & Chih-Chung Huang. (2022) Ca2+ signaling–mediated low-intensity pulsed ultrasound–induced proliferation and activation of motor neuron cells. Ultrasonics 124, pages 106739.
Crossref
Christina N. Fournier. (2022) Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design. Neurotherapeutics 19:4, pages 1180-1192.
Crossref
Mónica Povedano, Andrés Paipa, Miquel Barceló, Michael K. Woodward, Sandra Ortega, Raúl Domínguez, Maria Esperança Aragonés, Raquel Horrillo, Montserrat Costa & Antonio Páez. (2021) Plasma exchange with albumin replacement and disease progression in amyotrophic lateral sclerosis: a pilot study. Neurological Sciences 43:5, pages 3211-3221.
Crossref
Simon Witzel, André Maier, Robert Steinbach, Julian Grosskreutz, Jan C. Koch, Anastasia Sarikidi, Susanne Petri, René Günther, Joachim Wolf, Andreas Hermann, Johannes Prudlo, Isabell Cordts, Paul Lingor, Wolfgang N. Löscher, Zacharias Kohl, Tim Hagenacker, Christian Ruckes, Birgit Koch, Susanne Spittel, Kornelia Günther, Sebastian Michels, Johannes Dorst, Thomas Meyer & Albert C. Ludolph. (2022) Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurology 79:2, pages 121.
Crossref
Jonathan D. Glass & Christina N. Fournier. (2022) Unintended Consequences of Approving Unproven Treatments—Hope, Hype, or Harm?. JAMA Neurology 79:2, pages 117.
Crossref
Nancy Tarantino, Ileana Canfora, Giulia Maria Camerino & Sabata Pierno. (2022) Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle. Cells 11:3, pages 415.
Crossref
Jalil Tavakol-Afshari, Amir Reza Boroumand, Najmeh Kaffash Farkhad, Amir Adhami Moghadam, Sajad Sahab-Negah & Ali Gorji. (2021) Safety and efficacy of bone marrow derived-mesenchymal stem cells transplantation in patients with amyotrophic lateral sclerosis. Regenerative Therapy 18, pages 268-274.
Crossref
C. Quarracino, M. Bendersky, R. Rey & G. E. Rodríguez. (2020) Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina. Acta Neurologica Belgica 121:6, pages 1519-1523.
Crossref
Suzanne F. Cook, Thomas Rhodes, Courtney Schlusser, Steve Han, Chao Chen, Neta Zach, Venkatesha Murthy & Shreya Davé. (2021) A Descriptive Review of Global Real World Evidence Efforts to Advance Drug Discovery and Clinical Development in Amyotrophic Lateral Sclerosis. Frontiers in Neurology 12.
Crossref
K. Achtert & L. Kerkemeyer. (2021) The economic burden of amyotrophic lateral sclerosis: a systematic review. The European Journal of Health Economics 22:8, pages 1151-1166.
Crossref
Jeremy S. Lum, Mikayla L. Brown, Natalie E. Farrawell, Luke McAlary, Diane Ly, Christen G. Chisholm, Josh Snow, Kara L. Vine, Tim Karl, Fabian Kreilaus, Lachlan E. McInnes, Sara Nikseresht, Paul S. Donnelly, Peter J. Crouch & Justin J. Yerbury. (2021) CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background. Scientific Reports 11:1.
Crossref
Qi Zhou, Min Yuan, Weiwen Qiu, Wenfeng Cao & Renshi Xu. (2021) Preclinical studies of mesenchymal stem cells transplantation in amyotrophic lateral sclerosis: a systemic review and metaanalysis. Neurological Sciences 42:9, pages 3637-3646.
Crossref
Maximillian Taro William Lee, William Mahy & Mark David Rackham. (2021) The medicinal chemistry of mitochondrial dysfunction: a critical overview of efforts to modulate mitochondrial health. RSC Medicinal Chemistry 12:8, pages 1281-1311.
Crossref
Eva Parobkova & Radoslav Matej. (2021) Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degenerations: Similarities in Genetic Background. Diagnostics 11:3, pages 509.
Crossref
Matthew C. Kiernan, Steve Vucic, Kevin Talbot, Christopher J. McDermott, Orla Hardiman, Jeremy M. Shefner, Ammar Al-Chalabi, William Huynh, Merit Cudkowicz, Paul Talman, Leonard H. Van den Berg, Thanuja Dharmadasa, Paul Wicks, Claire Reilly & Martin R. Turner. (2020) Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology 17:2, pages 104-118.
Crossref
Sara Nikseresht, James B.W. Hilton, Kai Kysenius, Jeffrey R. Liddell & Peter J. Crouch. (2020) Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond. Life 10:11, pages 271.
Crossref
Christian Lunetta, Cristina Moglia, Andrea Lizio, Claudia Caponnetto, Raffaele Dubbioso, Fabio Giannini, Sabrina Matà, Letizia Mazzini, Mario Sabatelli, Gabriele Siciliano, Isabella Laura Simone, Gianni Sorarù, Antonella Toriello, Francesca Trojsi, Marcella Vedovello, Fabrizio D’Ovidio, Massimo Filippi & Andrea Calvo. (2020) The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. Journal of Neurology 267:11, pages 3258-3267.
Crossref
P. Masrori & P. Van Damme. (2020) Amyotrophic lateral sclerosis: a clinical review. European Journal of Neurology 27:10, pages 1918-1929.
Crossref
Christopher J. McDermott. (2019) Clinical trials in amyotrophic lateral sclerosis. Current Opinion in Neurology 32:5, pages 758-763.
Crossref
Elena Abati, Nereo Bresolin, Giacomo Comi & Stefania Corti. (2019) Advances, Challenges, and Perspectives in Translational Stem Cell Therapy for Amyotrophic Lateral Sclerosis. Molecular Neurobiology 56:10, pages 6703-6715.
Crossref
Rongyuan Chen, Chunsik Lee, Xianchai Lin, Chen Zhao & Xuri Li. (2019) Novel function of VEGF-B as an antioxidant and therapeutic implications. Pharmacological Research 143, pages 33-39.
Crossref
Chiara F. Valori, Giulia Guidotti, Liliana Brambilla & Daniela Rossi. 2019. Neuroglia in Neurodegenerative Diseases. Neuroglia in Neurodegenerative Diseases 227 272 .
Alex G. Karanevich, Luke J. Weisbrod, Omar Jawdat, Richard J. Barohn, Byron J. Gajewski, Jianghua He & Jeffrey M. Statland. (2018) Using automated electronic medical record data extraction to model ALS survival and progression. BMC Neurology 18:1.
Crossref
Alexander E. Volk, Jochen H. Weishaupt, Peter M. Andersen, Albert C. Ludolph & Christian Kubisch. (2018) Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Medizinische Genetik 30:2, pages 252-258.
Crossref
Hung Phuoc Nguyen, Christine Van Broeckhoven & Julie van der Zee. (2018) ALS Genes in the Genomic Era and their Implications for FTD. Trends in Genetics 34:6, pages 404-423.
Crossref
Merit Lamp, Paola Origone, Alessandro Geroldi, Simonetta Verdiani, Fabio Gotta, Claudia Caponnetto, Grazia Devigili, Lorenzo Verriello, Carlo Scialò, Corrado Cabona, Antonio Canosa, Irene Vanni, Emilia Bellone, Roberto Eleopra & Paola Mandich. (2018) Twenty years of molecular analyses in amyotrophic lateral sclerosis: genetic landscape of Italian patients. Neurobiology of Aging 66, pages 179.e5-179.e16.
Crossref
Bertold Schrank. (2018) Edaravone — neue Hoffnung für ALS-Patienten?. DNP - Der Neurologe & Psychiater 19:3, pages 42-44.
Crossref
Jonathan Kimmelman. (2018) Better to be in The Placebo Arm for Trials of Neurological Therapies?. Cell Transplantation 27:4, pages 677-681.
Crossref
Magdalena Kuźma-Kozakiewicz. (2018) Edaravone in the treatment of amyotrophic lateral sclerosis. Neurologia i Neurochirurgia Polska 52:2, pages 124-128.
Crossref
Giuseppe Battaglia & Valeria Bruno. (2018) Metabotropic glutamate receptor involvement in the pathophysiology of amyotrophic lateral sclerosis: new potential drug targets for therapeutic applications. Current Opinion in Pharmacology 38, pages 65-71.
Crossref